Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma

Clinical Cancer Research

Volumn 19, Issue 2, 2013, Pages 469-479

  Veal, Gareth J ^a   Errington, Julie ^a   Rowbotham, Sophie E ^a   Illingworth, Nicola A ^a   Malik, Ghada ^a   Cole, Michael ^a   Daly, Ann K ^b   Pearson, Andrew D J ^c   Boddy, Alan V ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN;

ADAPTIVE DOSING; ARTICLE; BEHAVIOR CHANGE; BLOOD TOXICITY; CHEILITIS; CHILD; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; FEMALE; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; INFANT; INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NEUROBLASTOMA; PERSONALIZED MEDICINE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SKIN TOXICITY;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; ISOTRETINOIN; MALE; NEUROBLASTOMA; TREATMENT OUTCOME;

EID: 84872543847     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2225     Document Type: Article

References (24)

1. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341: 1165-73.
2. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas- Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study. J Clin Oncol 2009;27: 1007-13.
3. Veal GJ, Cole M, Errington J, Pearson ADJ, Foot ABM, Whyman G, et al. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group. Br J Cancer 2007;96: 424-31.
4. van der Leede BM, van den Brink CE, Pijnappel WWM, Sonneveld E, van der Saag PT, van der Berg B. Autoinduction of retinoic acid metabolism to polar derivatives with decreased biological activity in retinoic acid-sensitive, but not in retinoic acid resistant human breast cancer cells. J Biol Chem 1997;272: 17921-8.
5. Kim SY, Yoo SJ, Kwon HJ, Kim SH, Byun Y, Lee K-S. Retinoic acid 4- hydroxylase-mediated catabolism of all-trans retinoic acid and the cell proliferation in head and neck squamous cell carcinoma. Metabolism 2002;51: 477-81.
6. Muindi J, Frankel SR, Miller WH, Jakubowski A, Scheinberg DA, Young CW, et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations - implications for relapse and retinoid resistance in patients with acute promyelocytic leukemia. Blood 1992;79: 299-303.
7. Miller VA, Rigas JR, Muindi JR, Tong WP, Venkatraman E, Kris MG, et al. Modulation of all-trans retinoic acid pharmacokinetics by liarozole. Cancer Chemother Pharmacol 1994;34: 522-6.
8. Chen H, Fantel AG, Juchau MR. Catalysis of the 4-hydroxylation of retinoic acids by cyp3a7 in human fetal hepatic tissues. Drug Metab Dispos 2000;28: 1051-7.
9. Marill J, Capron CC, Idres N, Chabot GG. Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids. Biochem Pharmacol 2002;63: 933-43.
10. Rowbotham SE, Boddy AV, Redfern CP, Veal GJ, Daly AK. Relevance of non-synonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug Metab Dispos 2010;38: 1261-6.
11. Rowbotham SE, Illingworth NA, Daly AK, Veal GJ, Boddy AV. Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans. Drug Metab Dispos 2010;38: 1211-7.
12. Bauters TG, Laureys G, Van de Velde V, Benoit Y, Robays H. Practical implications for the administration of 13-cis retinoic acid in pediatric oncology. Int J Clin Pharm 2011;33: 597-8.
13. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation - bioavailability, bioequivalence, and pharmacokinetic studies. J Pharmaceutical Sci 1992;81: 309-12.
14. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, et al. Genetic polymorphismof UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000;10: 679-85.
15. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27: 383-91.
16. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002;64: 1579-89.
17. Xie HG, Wood AJ, Kim RB, SteinCM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243-72.
18. Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NKC, et al. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 1995; 13: 894-901.
19. Kohler JA, Imeson J, Ellershaw C, Lie SO. A randomized trial of 13-cis retinoic acid in children with advanced neuroblastoma after high dose therapy. Br J Cancer 2000;83: 1124-7.
20. Matthay KK, Reynolds CP. Is there a role for retinoids to treat minimal residual disease in neuroblastoma? Br J Cancer 2000;83: 1121-3.
21. Reynolds CP, Schindler PF, Jones DM, Gentile JL, Proffitt RT, Einhorn PA. Comparison of 13-cis-retinoic acid to trans-retinoic acid using human neuroblastoma cell lines. Prog Clin Biol Res 1994;385: 237-44.
22. Veal GJ, Errington J, Redfern CPF, Pearson ADJ, Boddy AV. Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells. Biochem Pharmacol 2002;63: 207-15.
23. Khan AA, Villablanca JG, Reynolds CP, Avramis VI. Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patientswith neuroblastoma following bone marrow transplantation. Cancer Chemother Pharmacol 1996;39: 34-41.
24. Veal GJ, Boddy AV. Chemotherapy in newborns and preterm babies. Semin Fetal Neonatal Med 2012;17: 243-8.